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Autoantibodies (AAbs) to tumor-associated antigens (TAAs) have been identiﬁed in the circulation of patients with cancer. This
paper will focus on recent knowledge related to circulating AAbs to TAAs in breast carcinoma. So far, the following TAAs have
been identiﬁed to elicit circulating AAbs in breast carcinoma: p53, MUC-1, heat shock proteins (HSP-27, HSP-60, and HSP-90),
HER2/neu/c-erb B2, GIPC-1, c-myc, c-myb, cancer-testis antigens (NY-ESO-1), BRCA1, BRCA2, endostatin, lipophilin B, cyclin
B1, cyclin D1, ﬁbulin, insulin-like growth factor binding protein 2 (IGFBP-2), topoisomerase II alpha (TOPO2α), and cathepsin
D. Measurement of serum AAbs to one speciﬁc TAA only is of little value for screening and early diagnosis of breast carcinoma;
however, assessment of AAbs to a panel of TAAs may have promising diagnostic potential.
1.Introduction
The development of circulating autoantibodies (AAbs) to
tumor-associated antigens (TAAs) has been observed to
be associated with cancer [1, 2]. Unlike traditional tumor
markers (e.g., CA-15-3, CA-19-9, CA-125, and CEA), which
are soluble proteins shed by bulky tumors, serum AAbs to
TAAs are detectable even when the tumor is very small [2].
Thus, the identiﬁcation of AAbs to TAAs could potentially
be used as a novel tool for screening and early diagnosis
of cancer [2–6]. Sahin et al. [7] introduced in 1995 a
method called SEREX (serological analysis of recombinant
cDNA expression libraries) that has broad applicability to
the analysis of the humoral immune response to cancer.
Originally, they had used mRNA isolated from tumor tissue
with the assumption that speciﬁc TAAs could be isolated.
This has turned out to be incorrect, since there is no such
thing as a TAA that is only expressed in tumors. Thus, the
SEREX method as described by the original authors has been
highly modiﬁed and uses nowadays cDNA libraries from a
variety of cell lines and not just from tumor tissues. So far,
over 2,000 candidate TAAs in many types of human cancer
have been identiﬁed and separated into six categories [5, 8–
11]: (1) diﬀerentiation antigens (expressed by cancers and
a restricted subset of normal cells, e.g., tyrosinase, melan-
A/MART-1, NY-BR-1, and gp100), (2) mutational antigens
(e.g., CDK4, β-catenin, caspase-8, and p53), (3) ampliﬁ-
cation (overexpression) antigens (e.g., c-erb B2/HER2/neu,
NY-C0-58, and p53), (4) splice variant antigens (e.g., NY-
CO-37/PDZ-45, and ING1), (5) viral antigens (e.g., HPV
and EBV), and cancer-testis (CT) antigens (e.g., NY-ESO-
1, MAGE-A, and LAGE-1). The humoral immune response
elicited by TAAs could have two major clinical applications
[9]: (1) AAbs to TAAs could represent novel biomarkers
for cancer diagnosis, prognosis, monitoring, and prediction
of response to chemotherapy, (2) TAAs might be used
as targets for immunotherapy of cancer. Notwithstanding,
eﬀorts to predict cancer based on autoimmunity to either
an individual TAA or even tailor-made panel of TAAs have
not yet resulted in serologic biomarkers with deﬁnitive
predicting speciﬁcity and sensitivity [12]. It has, however,
been shown by some investigators that the use of tailor-made2 Journal of Oncology
panel of TAAs, rather than individual TAAs, enhances the
likelihoodofdetectingcancer-associatedAAbswithpotential
diagnostic value [3, 12].
In the USA, breast carcinoma is diagnosed in approxi-
mately 193,000 women and 2,000 men yearly with an age-
adjusted incidence of 125 new cases/100,000 women/year
and 1 new case/100,000 men/year, and it causes approxi-
mately 41,000 deaths (40,500 women and 500 men) each
year [13, 14]. Breast carcinoma is the ﬁrst most common
canceramongwomen(27%of allcancersinwomen)andthe
second most common cause of death from cancer, after lung
carcinoma, in women (15% of all cancer deaths in women)
[13]. The National Cancer Institute (NCI) has estimated
that 12.7% (1/8) of women born today in the USA will be
diagnosed with breast carcinoma at some time in their lives
[15] .T h eﬁ v e - y e a rs u rvi v a lra t eo v e ra llo fw o m e nwi t hb r e a s t
carcinoma in the USA is about 90% [14].
Worldwide, breast carcinoma is by far the most frequent
cancer among women with an estimated 1.38 million new
cases diagnosed in 2008 (23% of all malignancies in women)
and ranks second overall (10.9%), after lung carcinoma, of
all malignancies in both sexes [16]. The estimated incidence
of breast carcinoma in 2008 worldwide has been 39 new
cases/100,000 women. The incidence has been estimated to
vary from 19.3 in Eastern Africa to 89.9 in Western Europe,
and is high (greater than 80) in developed countries (except
Japan) and low (less than 40) in most of the developing
countries [16]. Breast carcinoma has been estimated to cause
458,000 deaths in 2008 worldwide (13.7% of all cancer
deaths in women and 6% of all cancer deaths in both
sexes). The estimated mortality from breast carcinoma in
2008worldwidehasbeen12.5deaths/100,000women.Breast
carcinoma is the most frequent cause of death from cancer in
women worldwide and the ﬁfth cause of death from cancer,
after lung, stomach, liver, and colorectal carcinoma, in both
sexes [16].
Current screening modalities for breast carcinoma diag-
nosis include mammography, ultrasound (US), and mag-
netic resonance imaging (MRI); however, there is still an
urgent need to develop an alternative modality of screening
for earlier diagnosis [17]. The use of serum-soluble tumor
antigens, such as CA-15-3 glycoprotein, as biomarkers for
detection of breast carcinoma has been limited by their
insuﬃcient speciﬁcity and sensitivity, particularly for organ
conﬁned early-stage disease. Consequently, CA-15-3 is not
recommended for use in the screening or detection of breast
carcinoma[18–21].ThisisinpartduetotheelevationofCA-
15-3 in benign conditions including breast, liver, and kidney
disorders and other cancers [22]. Thus, there is a need to
discover novel biomarkers, such as AAbs to speciﬁc breast
carcinoma TAAs, for screening, early diagnosis, prediction
of prognosis, and monitoring of treatment. There is also
a need to develop new therapeutic approaches, such as
immunotherapy, for the management of breast carcinoma.
T h ee s t a b l i s h m e n to fA A b st oT A A sa sb i o m a r k e r sf o rb r e a s t
carcinoma and the development of successful immunother-
apeutic strategies require the identiﬁcation and characteri-
zation of immunogenic breast carcinoma TAAs that will be
recognized by the host immune system. Thus far, only few
circulatingAAbstospeciﬁcbreastcarcinomaTAAshavebeen
identiﬁed and investigated. In breast carcinoma, like in other
malignancies, the use of tailor-made panel of TAAs, rather
than individual TAAs, enhances the likelihood of detecting
cancer-associated AAbs with potential diagnostic value.
This paper will review the up-to-date knowledge related
to AAbs against individual TAAs in breast carcinoma. Table 1
shows the frequency of identiﬁed AAbs to breast carcinoma
TAAs.
2.Autoantibodiestop53 Protein
The wild-type p53 gene is a tumor suppressor gene located
on chromosome 17p13 and encodes a 53-kDa nuclear phos-
phoprotein that normally acts as a guardian of the integrity
of the genome [27, 44, 45]. Mutations in p53 are the most
common genetic changes found in human malignancies
and the mutational status of p53 is prognostic in many
malignancies [46]. In breast carcinoma, p53 mutations have
been shown to be associated with worse overall and disease-
free survival, independent of other risk factors, and have
been implicated in resistance to anticancer therapies [47,
48]. Missense point mutations, which represent more than
85% of gene abnormalities, lead to a conformational change
which stabilizes the p53 protein and allows it to accumulate
in the nucleus to relatively high levels [27, 44, 45, 49–51].
Accumulation of the mutant p53 in tumor cells can elicit
a humoral immune response leading to the production of
anti-p53 AAbs [27]. Initially, it was thought that only tumors
with missense p53 mutations resulting in p53 overexpression
can elicit anti-p53 AAbs [27, 52–54]. Later on, however,
anti-p53 AAbs have also been detected in sera from patients
with tumors lacking p53 overexpression. Induction of anti-
p53 AAbs in these patients might be due to the unusual
presentationoflargeamountsofwild-typep53fromnecrotic
large tumors or metastases [27, 55]. Recently, it has been
shownthatanti-p53AAbsaredirectedagainstimmunodom-
inant epitopes localized in the amino and carboxy terminal
ends of the p53-protein, unrelated to the mutational hot
spot [27, 51, 56–58]. Epithelial ovarian carcinomas have
been regarded as a tumor entity associated with the highest
frequency (13%–46%) of circulating anti-p53 AAbs [59];
nevertheless, breast carcinomas are also associated with a
considerable incidence (2.8%–47.5%) of serum anti-p53
AAbs. Thus, breast carcinomas, alongside epithelial ovarian
carcinomas, are among the most immunogenic malignancies
inducing anti-p53 AAbs response. Indeed, while mutation
of p53 appears a seminal event in carcinogenesis and is
present in ∼30% of breast carcinoma patients, it is still
unclear why only a subset of p53 mutation-positive breast
carcinoma patients (∼50%) generates anti-p53 AAbs [27]. It
has been suggested that only p53 mutations that are localized
in exons 5 and 6 with an altered protein conformation and
that bind to HSP-70 are associated with anti-p53 AAbs [54,
58]. Further studies, however, have demonstrated that other
factors contribute to the humoral immune response to p53
protein and suggested that the capacity to elicit a humoral
immune response is linked to the biological backgroundJournal of Oncology 3
Table 1: Frequency of identiﬁed circulating AAbs to TAAs in breast carcinoma.
A A bt oT A A Positive Total % Comment Reference
p53 22
6a
94
40a
23.4
15.0a
Promising diagnostic potential when
incorporated in AAb assays to a panel of
TAAs
[23]
p53 11 24 45.8 Association with higher risk for relapse. [24]
p53 31 144 21.5
Correlation to higher stage, lymph node
metastasis, negative ER, positive c-erbB-2
and worse survival.
[25]
p53 8 101 7.9 Correlated neither with p53 cytosolic
assay nor with prognostic factors.
[26]
p53 22 220 10
Promising diagnostic potential when
incorporated in AAb assays to a panel of
TAAs
[1]
p53 296 2006 14.7
Summary of 15 studies (1979–1999).
Frequency of AAbs: 2.8%–47.5%. Few
studies showed association with high
grade and poor survival.
[27]
MUC1 19
9a
94
40a
20.2
22.5a
Promising diagnostic potential when
incorporated in AAb assays to a panel of
TAAs.
[23]
MUC1 22 4 8 . 3 No correlation to circulating mucin levels
or stage of disease.
[28]
MUC1 36b
11c
140b
61c
25.7b
18.0c
Inverse correlation to extent of disease.
Suggested role in protection against
disease progression.
[29]
MUC1 20 100 20
Promising diagnostic potential when
incorporated in AAb assays to a panel of
TAAs.
[1]
HSP-27 219 579 37.8 Association with improved survival. [30]
HSP-60 18
16a
58
49a
31
33a Promising diagnostic potential. [31]
HSP-90 46 125 36.8 Correlation to extent of disease.
Promising diagnostic potential.
[32]
HSP-90 135 214 63.1 Association with higher mortality rate. [33]
HER2/neu 16
5a
94
40a
17.0
12.5a
Promising diagnostic potential when
incorporated in autoantibody assays
against a panel of TAAs.
[23]
HER2/neu 11 20 55
HER2/neu oncoprotein elicits an
immune response and may be used as a
target for speciﬁc immunotherapy.
[34]
HER2/neub
12
9d
3e
107
44d
63e
11.2
20.4d
4.8e
Correlation to positive HER2/neu status
in the primary tumor (P = .03).
[35]
HER2/neuc 34 5 6 . 6
Incidence is lower in advanced-stage
disease compared to early-stage disease.
Suggested role in limiting disease
progression.
[36]
HER2/neu 30 225 13
Promising diagnostic potential when
incorporated in AAb assays to a panel of
TAAs.
[1]
GIPC-1 17 22 77 Promising diagnostic potential. [37]
c-myc 12
3a
94
40a
12.7
7.5a
Promising diagnostic potential when
incorporated in autoantibody assays
against a panel of TAAs
[23]
c-myb 31 72 43 No correlation to c-myb status in the
primary tumor.
[38]4 Journal of Oncology
Table 1: Continued.
A A bt oT A A Positive Total % Comment Reference
NY-ESO-1/ LAGE-1 25
3a
94
40a
26.6
7.5a
Promising diagnostic potential when
incorporated in autoantibody assays
against a panel of TAAs
[23]
BRCA1 8
1a
94
40a
8.5
2.5a
No diagnostic potential, even if
incorporated in autoantibody assays
against a panel of TAAs
[23]
BRCA2 32
9a
94
40a
34.0
22.5a
Promising diagnostic potential when
incorporated in autoantibody assays
against a panel of TAAs
[23]
Endostatin 24b
25c
36b
59c
66.6b
42.4c
Inverse correlation to extent of disease.
No correlation to circulating levels of
endostatin. Association with better
prognosis in advanced-stage disease.
[39]
Lipophilin B 20
13c
74
35c
27.0
37.1c
Correlation to extent of disease.
Promising diagnostic potential.
[40]
Cyclin D1 3 40 7.5 Questionable diagnostic potential [1]
Cyclin B1 3 7 42.8
Correlation to higher level of tumor
cyclin B1 expression. Questionable
diagnostic potential.
[41]
Fibulin 15 20 75 Promising diagnostic potential. [42]
IGFBP2 21 142 15 Questionable diagnostic potential [1]
IGFBP2 4 80 5 Questionable diagnostic potential [43]
TOPO2α 8 115 7 Questionable diagnostic potential [1]
Cathepsin D 5 100 5 Questionable diagnostic potential [1]
aDuctal carcinoma in situ (DCIS).
bEarly-stage disease.
cAdvanced-stage disease.
dHER2/neu-positive tumor.
eHER-2/neu-negative tumor.
of the patients [27, 52]. It is possible that for an identical
mutation, the humoral immune response is dependent on
the speciﬁc combination of MHC class I and II molecules
expressed by each individual [27].
Dalifard et al. [26] demonstrated by ELISA in 1999 that
anti-p53 AAbs were present in the sera of 8/101 (7.9%)
patients with breast carcinoma. The presence of serum anti-
p53AAbscorrelatedneitherwithp53cytosolicassaynorwith
prognostic factors. The authors concluded that serum anti-
p53AAbassayisnotusefulfortheselectionofpatientgroups
with poor prognosis [26].
Soussi [27] surveyed the literature from 1979 through
1999 on anti-p53 AAbs in the sera of patients with various
types of cancer. Serum anti-p53 AAbs were present in
1600/9489 (16.8%) patients with diﬀerent malignancies and
in 35/2404 (1.4%) healthy controls (P<10
−4). Fifteen
studies [52, 54, 58, 60–71] examined anti-p53 AAbs in the
sera of breast carcinoma patients. The frequency of anti-
p53 AAbs in the sera of breast carcinoma patients ranged
in these studies from 2.8% to 47.5%. Overall, the presence
of anti-p53 AAbs was demonstrated in the sera of 296/2006
(14.7%) breast carcinoma patients [27]. χ2 test showed that
the frequency of anti-p53 AAbs was signiﬁcantly higher in
the sera of breast carcinoma patients compared to healthy
controls (P<10
−4)[ 27]. Since serum anti-p53 AAbs
are truly rare in the normal population, the speciﬁcity of
this assay for the detection of breast carcinoma has been
estimated to attain 95%. Nevertheless, since anti-p53 AAbs
were present on the average in the sera of only 15% of
breast carcinoma patients, the sensitivity of this assay for the
detection of breast carcinoma has been estimated to reach
only 30% [27]. Five studies [58, 60, 63, 65, 67] indicated
that serum anti-p53 AAbs are found in patients with tumors
that have high grades and/or that are negative for steroid
hormone receptors, two clinical parameters known to be
associated with p53 mutations and bad prognosis. Two
studies [67, 68] found an association between serum anti-
p53 AAbs and short survival whereas one study [71] did
not ﬁnd any association, and another study [66]f o u n da n
association with good survival.
Regele et al. [24] demonstrated by ELISA in 2003 that
serum anti-p53 AAbs were present in 11/24 (45.8%) patients
at initial diagnosis of breast carcinoma. In seven of these 11
patients, therapy was paralleled by decreasing anti-p53 AAb
titers; in four, relapse was preceded by an increase of the titer.
Two patients, who initially tested negative, seroconverted
to anti-p53 AAb positivity upon relapse. The authors [24]
concluded that monitoring of serum anti-p53 AAbs duringJournal of Oncology 5
followup can be informative about the clinical course of the
disease and the development of breast carcinoma relapse can
be preceded by an increase of serum anti-p53 AAb titer.
Gao et al. [25] showed by ELISA in 2005 that serum
anti-p53 AAbs were present in 31/144 (21.5%) patients with
breast carcinoma and 12/242 (4.9%) healthy controls. The
presence of serum anti-p53 AAbs was associated with several
poor prognostic factors including higher clinical stage (P =
.0233), lymph nodes metastasis (P = .0033), negative ER
expression (P = .0250) and positive HER2/c-erbB-2 status
(P = .0227). There was also a strong correlation between
serum anti-p53 AAbs and tumor immunohistochemical
positivity for p53 (P<. 0001). The authors [25] speculated
that serum anti-p53 AAbs could serve as a useful and
convenient marker for the detection and prognosis of breast
carcinoma.
Chapman et al. [23] showed by ELISA in 2007 that
preoperative serum anti-p53 AAbs were present in 22/94
(23.4%) patients with newly diagnosed breast carcinoma
and 6/40 (15%) patients with ductal carcinoma in situ.
Positive seroreactivity was deﬁned as an absorbance value
greater than the mean plus two standard deviations of a
normal cohort. The sensitivity and speciﬁcity were 24% and
96%, respectively, for breast carcinoma, and 15% and 96%,
respectively, for ductal carcinoma in situ. The authors [23]
concluded that measurement of serum AAbs to p53 protein
only is of little value for screening and early diagnosis of
breast carcinoma; however, AAbs to p53 may have promising
diagnosticpotentialwhenincorporatedinAAbassaysagainst
ap a n e lo fT A A s .
Lu et al. [1] demonstrated with ELISA in 2008 that AAbs
to p53 protein were present in the sera of 22/220 (10%)
breast carcinoma patients compared to 2/200 (1%) healthy
controls. It has been concluded that AAbs to p53 have no
diagnostic potential when examined alone; however, they
may possibly have diagnostic potential when incorporated in
AAB assays to a panel of TAAs.
3. Autoantibodiesto MUC1 Protein
Polymorphic epithelial mucin (PEM, MUC1), a human
mucin family member, is a high-molecular-weight (over
400kDa) transmembrane glycoprotein. It is expressed in a
hyperglycosylated form and low levels by many types of
normal epithelial cells and in a hypoglycosylated form and
high levels by most epithelial adenocarcinomas including
breast and ovarian carcinoma [72, 73]. About one-quarter of
breast and ovarian carcinoma patients have circulating AAbs
to MUC1, either free or bound to immune complexes. While
the presence of these immune complexes has prognostic
signiﬁcance in cancer patients, the signiﬁcance of free AAbs
to MUC1 is less clear [74]. AAbs to MUC1 have been
described and correlated with a more favorable prognosis;
thus,itseemsthatriskforbreastcarcinomamightbereduced
by preexisting MUC1-speciﬁc immunity [75, 76].
UsingELISA,Koteraetal.[28]demonstratedin1994that
anti-MUC1 AAbs were present in the sera of 2/24 (8.3%)
breast carcinoma, 2/12 (16.7%) pancreatic carcinoma, and
1/10 (10%) colon carcinoma patients. Overall, the presence
or absence of serum anti-MUC1 AAbs did not correlate
with the levels of circulating mucin or stage of disease [28].
von Mensdorﬀ-Pouilly et al. [29] demonstrated by sandwich
enzyme-linked immunoassay in 1996 that anti-MUC1 AAbs
were present in the sera of 2/96 (2.1%) healthy controls,
15/40 (37.5%) patients with benign breast tumor, 36/140
(25.7%) patients with early-stage breast carcinoma and
11/61 (18%) patients with advanced-stage breast carcinoma.
Serum anti-MUC1 AAbs were elevated in 24/74 (32.4%)
node-negative patients and in 12/59 (20.3%) node-positive
p a t i e n t sa n da b s o l u t ev a l u e sw e r eh i g h e ri nn o d e - n e g a t i v e
patients (P = .0168). There was an inverse correlation
between positivity for serum anti-MUC1 AAbs and extent
of disease; while 3/6 (50%) patients with a carcinoma in
situ were positive, only 1/15 (6.7%) patients with more
than ﬁve nodes involved had elevated levels of anti-MUC1
AAbs. All seven patients with distant metastases at ﬁrst
diagnosis were anti-MUC1 AAb-negative. Twenty-eight of
133 patients had a recurrence during followup; 23 (82%) of
these 28 patients were anti-MUC1 AAb-negative at the time
of ﬁrst diagnosis. The 5-year survival of 13 patients who had
elevated pretreatment serum levels of CA-15-3 (>30U/mL)
and were anti-MUC1 AAb-positive was better than the 5-
year survival of 41 patients who had elevated pretreatment
serum levels of CA-15-3 and were anti-MUC1 AAb-negative
(100% versus 71%, P = .0457). The authors [29]s u g g e s t e d
that a natural humoral immune response to MUC1 seems
to protect against disease progression, while lack of immune
reaction, or immune tolerance developing in the course of
disease, could be an additional risk factor more frequently
associated with an unfavorable outcome.
Chapmanetal.[23]showedbyELISAin2007thatserum
anti-MUC1 AAbs were present in 19/94 (20.2%) patients
with newly diagnosed breast carcinoma and 10/40 (25%)
patients with ductal carcinoma in situ. Positive seroreactivity
w a sd e ﬁ n e da sa na b s o r b a n c ev a l u eg r e a t e rt h a nt h em e a n
plus two standard deviations of a normal cohort. The
sensitivity and speciﬁcity were 20% and 98%, respectively,
for breast carcinoma, and 23% and 98%, respectively, for
ductal carcinoma in situ. The authors [23] concluded that
measurement of serum AAbs to MUC1 protein only is
of little value for screening and early diagnosis of breast
carcinoma; however, AAbs to MUC1 may have promising
diagnosticpotentialwhenincorporatedinAAbassaysagainst
ap a n e lo fT A A s .
Lu at al. [1] observed an increased AAb response to p53,
HER-2, MUC1, topoisomerase II alpha (TOPO2α), insulin-
like growth factor binding protein 2 (IGFBP2), cyclin D1,
and Cathepsin D in breast carcinoma patients. Nonetheless,
the most frequently encountered AAb response was directed
against MUC1 protein, which was detected in 20/100 (20%)
breast carcinoma patients compared to 3/100 (3%) healthy
controls [1].
Obviously, serum AAb-assay against MUC1 protein only
is of little value for screening and early diagnosis of breast
carcinoma; however, AAbs to MUC1 may have promising
diagnosticpotentialwhenincorporatedinAAbassaysagainst
a panel of TAAs. Moreover, there is support for the notion6 Journal of Oncology
that preexisting AAbs to MUC1 may reduce the risk of
developing breast carcinoma and presence of AAbs to MUC1
in breast carcinoma is correlated with a more favorable
prognosis.
4. Autoantibodiesto Heat-Shock Proteins
Heat-shockproteins(HSPs)arecytoplasmicproteinsthatact
as molecular chaperones for protein molecules in various
intracellular processes. They play an important role in
protein-protein interactions, including folding and confor-
mation and prevention of inappropriate protein aggregation.
They are called heat-shock proteins since they were ﬁrst
discovered in cells exposed to high temperatures. How-
ever, their synthesis is also accentuated under other stress
conditions, such as exposure of the cell to inﬂammation,
infection, ischemia, toxins, cytotoxic drugs, and malignant
transformation. HSPs have been classiﬁed into families
according to their molecular weight [77–79].
Overexpression of HSP-27 in breast carcinoma has been
associated with shorter disease-free survival [30, 80, 81].
Conroy et al. [30] demonstrated by ELISA in 1998 that
serum AAbs to HSP-27 were present in 219/579 (37.8%)
breast carcinoma patients compared to 1/53 (1/9%) healthy
subjects (P<. 001). The mortality rate was lower in
women with AAbs to HSP-27 than in those who lacked such
AAbs (P = .006). Thus, a signiﬁcant association has been
found between the presence of serum AAbs to HSP-27 and
improved survival in breast carcinoma patients [30].
HSP-60 is an abundant, highly conserved protein mostly
localized in the mitochondrial matrix. It plays a role in
the regulation of various cellular functions and assists in
mitochondrial protein folding, unfolding, and degradation.
HSP-60 is involved also in the process of apoptosis and
interacts with proteins implicated in cell cycle regulation
[31]. With use of ELISA, Desmetz et al. [31] demonstrated
the presence of serum AAbs to HSP-60 (seropositivity was
deﬁned as a value greater than the mean of the normal
population plus two standard deviations) in 16/49 (32.6%)
ductal carcinoma in situ (DCIS) patients and 18/58 (31%)
early-stage breast carcinoma patients compared to 4/93
(4.3%) healthy subjects. This corresponded to a signiﬁcant
diﬀerence between DCIS patients (P<. 0001) or early-stage
breast carcinoma patients (P<. 0001) and healthy controls.
The frequency of AAbs to HSP-60 was signiﬁcantly higher
in high-grade DCIS patients (11/23, 47.8%) compared to
low-grade DCIS patients (5/26, 19.2%) (P = .0188). This
correspondedtoahighersigniﬁcantdiﬀerencebetweenhigh-
grade DCIS patients and healthy controls (P<. 0001) than
between low-grade DCIS patients and healthy controls (P =
.0233) [31]. The diagnostic performance (discriminating
between breast carcinoma patients and healthy subjects)
of AAbs to HSP-60 was represented by a speciﬁcity of
95.7%, sensitivity of 31.8%, positive predictive value of
89.5%, negative predictive value of 54.9%, and area under
curve (AUC) of 63.7% [31]. Notably, no signiﬁcant relation
was found between the frequency of AAbs to HSP-60 and
estrogen receptor (ER), progesterone receptor (PR) and
HER-2 status [31]. It seems that measuring AAbs to HSP-
60 has promising diagnostic potential for early detection
of breast carcinoma; however, this is still inconclusive and
further studies are needed.
Conroy et al. [32] demonstrated by ELISA in 1995 that
serumAAbstoHSP-90werepresentin46/125(36.8%)breast
carcinoma patients. Seropositivity was deﬁned as a value
greaterthanthemeanvalueobservedinnormalcontrolsplus
three standard deviations. Multivariate analysis indicated
that the presence of serum AAbs to HSP-90 (P<. 04)
and the presence of axillary lymph node invovlement (P<
.001) correlated with the development of metastases [32].
Moreover, the presence of serum AAbs to HSP-90 correlated
with the development of metastases even in patients without
a x i l l a r yl y m p hn o d ei n v o l v e m e n t[ 32]. In 1998, Conroy et
al. [33] showed by ELISA that serum AAbs to HSP-90 were
present in 135/214 (63.1%) breast carcinoma patients before
surgery and 127/200 (63.5%) breast carcinoma patients
after surgery. Mortality rate from breast carcinoma was
greater in women testing positive for AAbs to HSP-90 than
those testing negative for AAbs to HSP-90. Although the
diﬀerence between the two groups did not attest statistical
signiﬁcance,theauthorshaveconcludedthatthereappearsto
be an association between higher mortality rate from breast
carcinoma and presence of serum AAbs to HSP-90 [33].
5.Autoantibodiesto
HER2/Neu/c-ErbB2(p185) Protein
HER2/Neu/ErbB2 is a member of the epidermal growth
factor receptor (EGFR) family that is ampliﬁed and overex-
pressed in 20%–30% of breast carcinomas. HER2-positive
breast carcinoma yields a poor patient prognosis due to
a high incidence of metastases and intrinsic resistance to
endocrine and conventional chemotherapy. Treatments that
target HER2 expression in cancer cells have been shown to
be useful strategies to signiﬁcantly reverse the malignancy
induced by HER2 overexpression [82].
Serum anti-HER2 AAbs were detected by ELISA in
16/94(17%)patientswithnewlydiagnosedbreastcarcinoma
and 5/40 (12.5%) patients with ductal carcinoma in situ
[23]. Positive seroreactivity was deﬁned as an absorbance
value greater than the mean plus two standard deviations
of a normal cohort. The sensitivity and speciﬁcity were
18% and 94%, respectively, for breast carcinoma, and 13%
and 94%, respectively, for ductal carcinoma in situ. It has
been concluded that measurement of serum AAbs to HER2
proteinonlyisoflittlevalueforscreeningandearlydiagnosis
o fb r e a s tc a r c i n o m a ;h o w e v e r ,A A b st oH E R 2m a yh a v e
promising diagnostic potential when incorporated in AAb
assays against a panel of TAAs [23].
Disis et al. [34] demonstrated by western blot analysis
in 1994 that serum anti-HER2 AAbs are present in 11/20
(55%) patients with breast carcinoma. They conﬁrmed that
the HER2 oncoprotein elicits an immune response and spec-
ulated that the HER2 oncoprotein may be used as a target
for speciﬁc immunotherapy [34]. In 1997, Disis et al. [35]
showed by capture enzyme-linked immunosorbent assayJournal of Oncology 7
(ELISA) and veriﬁed by western blot analysis that serum
anti-HER2 AAbs, at titers of > or = 1:100, were present in
12/107 (11.2%) early-stage breast carcinoma patients and in
none (0%) of 200 healthy controls (P<. 01). The presence
of serum anti-HER2 AAbs correlated to overexpression of
HER2 protein in the patient’s primary tumor. Nine of 44
(20.4%) patients with HER2-positive tumor had serum anti-
HER2 AAbs, whereas only 3/63 (4.8%) patients with HER2-
negative tumor had serum anti-HER2 AAbs (P = .03). In
contrast to the previous study, Disis et al. [16, 36]o b s e r v e d
in 2000 that serum anti-HER2 AAbs were present in only
3/45 (6.6%) advanced-stage breast carcinoma patients. The
lower incidence of serum anti-HER2 AAbs in advanced-
stage disease compared to early-stage disease suggests that
the humoral immune response to HER2 may have a role in
limiting breast carcinoma progression.
Lu et al. [1] demonstrated by recombinant ELISA that
AAbs to HER2 protein were present in the sera of 30/225
(13%) breast carcinoma patients compared to 10/200 (5%)
healthy controls. It seems that serum AAbs to HER2 have
no diagnostic potential when examined alone (unacceptable
high false negative rate); however, they may possibly have
diagnostic potential when incorporated in AAb assays to a
panel of TAAs.
6.Autoantibodiesto GIPC-1Protein
TheproteinknownasGIPC-1,amemberofafamilyofPDZ-
domain conserved proteins, is involved in regulation of G-
protein signaling and is upregulated in breast and ovarian
carcinomas [37, 83–85]. With use of 27.B1 and 27.F7 human
monoclonal antibody speciﬁc to GIPC-1 protein, Yavelsky
et al. [83] demonstrated a positive immunnohistochemical
staining for GIPC-1, respectively, in 24/25 (96%) and 11/23
(48%) breast ductal carcinomas, 9/10 (90%) and 8/15
(53%) breast lobular carcinomas, 0/4 and 0/4 breast ductal
carcinomas in situ, 0/4 and 0/4 breast lobular carcinomas
in situ, 0/4 and 0/4 breast ﬁbroadenomas, and 0/4 and
0/4 breast hyperplasias. GIPC-1 staining with 27.B1 and
27.F7 antibodies was positive only in invasive breast carci-
nomas (27.B1 displayed a higher reactivity rate than 27.F1)
whereas GIPC-1 staining with 27.B1 and 27.F7 antibodies
was negative in in situ and benign tumors (P<. 001). The
authors[83]assumethatGIPC-1proteiniscancer-associated
and hypothesize that serum AAbs to GIPC-1 may possibly
serve as a marker for invasive breast carcinoma. With use
of a novel technique of chemiluminescent optical ﬁber
immunoassay (the instrument is called chemiluminescent
optical ﬁber immunosensor), Salama et al. [37]t e s t e ds e r a
from 22 breast carcinoma patients, 11 epithelial ovarian
carcinoma patients, and healthy controls for the presence of
IgM anti-GIPC-1 AAbs. The chemiluminescent optical ﬁber
immunosensor detected 77% and 54% anti-GIPC-1 AAbs
positive sera within breast and ovarian carcinoma patients,
respectively, as compared to ELISA, which only detected 27%
and 18%, respectively [37]. The authors conclude that the
chemiluminescent optical ﬁber immunoassay is an eﬃcient
technique for prompt detection of AAbs to TAAs and, thus,
foresee that the newly developed chemiluminescent optical
ﬁber immunosensor might serve as an eﬃcient tool for early
diagnosis of breast and ovarian carcinomas [37].
7.Autoantibodiestoc-myc andc-myb Protein
The myc gene encodes for a transcription factor, c-myc
protein, that is essential for cell growth and proliferation
and is broadly implicated in tumorigenesis [86–88]. Serum
anti-c-myc AAbs were detected by ELISA in 12/94 (12.7%)
patients with newly diagnosed breast carcinoma and 3/40
(7.5%) patients with ductal carcinoma in situ [23]. Positive
s e r o r e a c t i v i t yw a sd e ﬁ n e da sa na b s o r b a n c ev a l u eg r e a t e r
than the mean plus two standard deviations of a normal
cohort. The sensitivity and speciﬁcity were 13% and 97%,
respectively, for breast carcinoma and 8% and 97%, respec-
tively, for ductal carcinoma in situ. It has been concluded
that measurement of serum AAbs to c-myc protein only is
of little value for screening and early diagnosis of breast
carcinoma; however, AAbs to c-myc may have promising
diagnosticpotentialwhenincorporatedinAAbassaysagainst
ap a n e lo fT A A s[ 23].
The Myb gene encodes for a transcription factor, c-myb
protein, that is required during multiple stages of T cell
development and is involved in cell cycle G1/S transition and
antiapoptosis [89, 90]. Using Western blotting, Sorokine et
al. [38] demonstrated that IgG AAbs against c-myb protein
were present in the sera of 31/72 (43%) breast carcinoma
patients compared to 12/49 (24.5%) healthy controls (P =
.036). No signiﬁcant correlation was observed between the
presence of circulating AAbs to c-myb protein and the
expression of the c-myb gene in breast tumors.
8. Autoantibodiesto NY-ESO-1Protein
Cancer-testis (CT) antigens are encoded by a group of
genes predominantly expressed in human germline cells.
They are downregulated in somatic adult tissues but may
become aberrantly expressed in several types of cancers. CT
antigens mapping to chromosome X are referred to as CT-X
antigens and distinguished from non-X CT antigens located
on autosomes [91, 92]. The CT-X antigens represent more
than half of all CT antigens and their expression is frequently
associated with a poorer outcome and higher grade and
advanced stage tumors [91, 92]. Only few studies have
explored the presence of CT antigens (NY-ESO-1 and/or
MAGE-A) in breast carcinoma rendering contradictory
results [93–95]. Interestingly, recent studies showed elevated
expression of the CT antigens, NY-ESO-1 and MAGE-A,
in triple-negative (ER-negative, PR-negative, and HER2-
negative) breast carcinomas [91, 96].
Serum anti-NY-ESO-1 AAbs were identiﬁed by ELISA
in 25/94 (26.6%) patients with newly diagnosed breast car-
cinoma and 3/40 (7.5%) patients with ductal carcinoma in
situ[23].Positiveseroreactivitywasdeﬁnedasanabsorbance
value greater than the mean plus two standard deviations of
a normal cohort. The sensitivity and speciﬁcity were 26%
and 94%, respectively, for breast carcinoma, and 8% and8 Journal of Oncology
94%, respectively, for ductal carcinoma in situ. It has been
concluded that measurement of serum AAbs to NY-ESO-1
proteinonlyisoflittlevalueforscreeningandearlydiagnosis
of breast carcinoma; however, AAbs to NY-ESO-1 may have
promising diagnostic potential when incorporated in AAb
assays against a panel of TAAs [23].
9. Autoantibodiesto BRCA Protein
Thewild-typeBRCAgenes,BRCA1(locatedonchromosome
17q21) and BRCA2 (located on chromosome 13q12-13),
are tumor-suppressor genes. The 185delAG and 5382insC
mutations in the BRCA1 gene and the 6174delT mutation
in the BRCA2 gene have been found to be signiﬁcantly more
c o m m o na m o n gA s h k e n a z iJ e w s( J e w so fe a s t e r nE u r o p e a n
ancestry) (1 in 40, 2.5%) in comparison to the general
population (1 in 800 to 1in 300, 0.12%–0.33%). Carriers of
these “Ashkenazi mutations” have a signiﬁcantly increased
lifetime risk of breast carcinoma (about 50%), ovarian
carcinoma and other carcinomas as compared to noncarriers
[97].
AAbs to BRCA1 and BRCA2 protein were identiﬁed
by ELISA in the sera of 8/94 (8.5%) and 32/94 (34%)
invasive breast carcinoma patients, respectively, and 1/40
(2.5%) and 9/40 (22.5%) ductal carcinoma in situ patients,
respectively [23]. Positive seroreactivity was deﬁned as an
absorbance value greater than the mean plus two standard
deviations of a normal cohort. The sensitivity and speciﬁcity
of evaluating serum anti-BRCA1 AAbs were 8% and 91%,
respectively, for invasive breast carcinoma, and 3% and 91%,
respectively, for ductal carcinoma in situ. The sensitivity and
speciﬁcity of evaluating serum anti-BRCA2 AAbs were 34%
and 92%, respectively, for invasive breast carcinoma, and
23% and 92%, respectively, for ductal carcinoma in situ.I t
has been concluded that (1) assessment of serum AAbs to
BRCA1 protein alone is of no value for screening and early
diagnosis of breast carcinoma, (2) serum AAbs to BRCA1
have no diagnostic potential even if incorporated in AAb
assays against a panel of TAAs, (3) assessment of serum AAbs
to BRCA2 protein alone is of little value for screening and
early diagnosis of breast carcinoma, and (4) serum AAbs to
BRCA2 may have, however, promising diagnostic potential
when incorporated in AAb assays against a panel of TAAs
[23].
10.AutoantibodiestoEndostatinProtein
Endostatin, one of the most potent known natural inhibitors
of angiogenesis, is a C-terminal fragment of collagen XVIII,
whichishighlyexpressedintheperivascularbasementmem-
brane of tumor-associated blood vessels [98, 99]. Elevated
serum levels of endostatin have been found in metastatic
cancerpatientsandhavebeencorrelatedtotheclinicalcourse
of the disease in various tumor types [39, 100].
Bachelot et al. [39] examined in 2006 with use of
Western blotting approach the immunoreactivity of serum
samples of breast carcinoma patients against recombinant
human endostatin and found an inverse correlation between
the incidence of naturally occurring serum antiendostatin
AAbs and extent of disease. Serum antiendostatin AAbs
were detected in 4/24 (16%) healthy women, 24/36 (66.6%)
patients with localized breast carcinoma, and 25/59 (42.4%)
patients with metastatic breast carcinoma. Diﬀerences were
statistically signiﬁcant between all breast carcinoma patients
and healthy controls (P<. 0001) and between localized
and metastatic breast carcinoma patients (P = .03). The
detection of serum antiendostatin AAbs was correlated to
better survival in metastatic breast carcinoma patients. The
median survival time of the 25 patients with detectable
serum anti-edostatin AAbs was 20 months compared to 7
months for the other 34 patients (P = .03). There was no
correlation to circulating levels of endostatin. The authors
[39] have concluded that a natural immune reaction against
endostatin can occur in breast cancer patients. The incidence
of serum antiendostatin AAbs is higher in patients with
localized disease and is associated with a better prognosis
in patients with metastatic disease. It has been suggested
that the reaction of anti-edostatin AAbs against tumor
blood vessels may slow down tumor progression in breast
carcinoma patients and partially explain the better survival
of serum antiendostatin AAb-positive patients [39].
11. Autoantibodiesto Lipophilin B Protein
Lipophilins and mammaglobins are members of the utero-
globin family, and mammaglobin has been shown to be
highly breast tissue speciﬁc [101, 102]. More recently,
lipophilin B, which is also present in breast tissue and
other tissues, has been identiﬁed as forming a complex
with mammaglobin that is potentially secreted into serum
[103, 104].
Carter et al. [40] observed in 2003 that preexisting
AAbs to lipophilin B peptide are absent in 20 healthy
donor sera and 30 lung carcinoma sera, but present in the
sera of 20/74 (27%) breast carcinoma patients overall, and
13/35 (37.1%) advanced-stage (stage IV) breast carcinoma
patients. This immune response was diﬀerent from that seen
to recombinant mammaglobin and native mammaglobin-
lipophilin B complex. The authors [40] have suggested that
the humoral immune responses to lipophilin B may serve as
a diagnostic indicator, particularly for breast carcinoma.
12. Autoantibodiesto CyclinProteins
Cyclins are molecules that control the progression through
the cell cycle. Cyclin B1 is important in the cell cycle
progression from G2-to-M phase and has been shown to be
overexpressed in several tumors [41, 105]. Several studies
[3, 106] have shown that serum AAbs to cyclin B1 protein
can be found in patients with various tumors and might be a
useful diagnostic marker in combination with AAbs against
several other tumor antigens. Suzuki et al. [41] examined
by ELISA the presence of serum AAbs to cyclin B1 in 120
patients (7 with breast carcinoma, 17 with pancreatic cancer,
27 with colon cancer, and 69 with lung cancer) and found
that the highest proportion of patients strongly positiveJournal of Oncology 9
(absorbance ≥1) for AABs to cyclin B1 was in the breast
carcinoma group (3/7, 42.8%). A correlation of serum AAbs
to cyclin B1 to higher level of tumor cyclin B1 expression
was found. AAbs to cyclin B1 in patients with breast and
colon carcinoma were primarily of the IgG isotype whereas
patients with pancreatic and lung carcinoma had in addition
AAbs of the IgA isotype. The authors [41] have speculated
that anticyclin B1 AAbs may have a role as a serum marker
for early detection of cancer.
Lu et al. [1] demonstrated by recombinant ELISA the
presence of serum AAbs to cyclin D1 in 3/40 (7.5%)
breast carcinoma patients compared to 4/80 (5%) healthy
controls. It seems that AAbs to cyclin D1 protein have no
diagnostic potential when examined alone; however, they
may possibly have diagnostic potential when incorporated in
autoantibody assays against a panel of TAAs.
13. Autoantibodiesto FibulinProtein
Fibulin-1(Fbln-1) is a member of an emerging family of
glycoproteins found in extracellular matrix (ECM) and
blood and has been observed to inhibit in vitro adhesion and
motilityofvariouscarcinomacelllines[107,108].Fbln-1has
beenimplicatedashavingaroleincancer,especiallyinbreast
carcinoma, and possible involvement in triggering protective
antitumor immune responses [109–112].
With use of SEREX, serum AAbs to the glycoprotein
Fbln-1 were identiﬁed in 15/20 (75%) breast carcinoma
patients compared to 4/20 (25%) healthy controls (P<
.0006) [42, 110]. It has been concluded that the SEREX-
deﬁned molecule Fbln-1 is able to elicit both cellular and
humoral immune responses in breast carcinoma patients.
The ﬁnding that Fbln-1 expression is associated with
improved survival in patients with lymphoid inﬁltrate at the
tumor site suggests the possible involvement of Fbln-1 in
triggering protective antitumor immune responses [112]. In
addition, it has been suggested that AAbs to Fbln-1 may
perhaps be exploited as a tool for early detection of breast
carcinoma [111].
14. Autoantibodiesto Insulin-LikeGrowth
Factor Binding Protein2 (IGFBP-2)
The insulin-like growth factors, IGF-1 and IGF-2, the type
1 and type 2 IGF receptors, and the six known IGF binding
proteins, IGFBP-1–6, comprise a complex system of peptide
hormones, cell surface receptors and circulating factors
involved in the regulation of growth, survival and diﬀeren-
tiation in a vast number of tissues [113]. The IGFBPs are
secretory proteins and possess an 80% sequence homology
witheachother,reservingbindingpreferencesforeitherIGF-
1 or IGF-2 [114]. IGFBPs have been proposed to have the
following functions: (1) to act as transport carrier proteins
of IGFs, (2) to stabilize and prolong the half-lives of IGFs
thereby regulating their metabolic clearance, (3) to provide
a means of tissue- and cell- type- speciﬁc localization, and
(4) to directly stimulate or inhibit interactions of the IGFs
with their receptors [114]. The IGFBP-2 is a 36kDa secretory
protein which, unlike other IGFBPs, is not glycosylated and
occurs only in its nonphosphorylated form.
Lu et al. [1] demonstrated by recombinant ELISA the
presence of AAbs to (IGFBP-2) in the sera of 21/142 (15%)
breast carcinoma patients compared to 2/100 (2%) healthy
controls. Goodell et al. [43]d e m o n s t r a t e db ys p e c i ﬁ c a l l y
designed his-tagged capture ELISA (based on lysate from
genetically engineered Chinese hamster ovary cells) the
presence of AAbs to IGFBP-2 in the sera of 4/80 (5%)
breast carcinoma patients, 32/80 (40%) colorectal carcinoma
patients and 2/200 (1%) healthy controls. These corre-
sponded to a signiﬁcant diﬀerence between all carcinoma
patients and healthy controls (P = .008), between breast
carcinoma patients and healthy controls (P = .032), and
between colorectal carcinoma patients and healthy controls
(P<. 001) [43]. The authors concluded that the AAbs to
IGFBP-2 assayed by capture ELISA can discriminate between
cancer patients and controls [43]. It seems, however, that
AAbs to IGFBP-2 have little value for screening and early
diagnosis of breast carcinoma when examined alone. AAbs
to IGFBP-2 may perhaps have diagnostic potential when
incorporated in AAb assays against a panel of TAAs.
15.Autoantibodiesto TOPO2α Protein
Topoisomerase II is a ubiquitous enzyme that regulates DNA
under- and overwinding, and removes knots and tangles
from the genome. Its two homologous isoforms, topoiso-
merase IIα and topoisomerase IIβ, share ∼70% amino acid
sequence identity and display similar enzymatic activities.
Topoisomerase IIα (TOPO2α) is an essential enzyme, and its
levels increase dramatically during periods of cell growth. It
is tightly associated with mitotic chromosomes and has an
essential role during DNA replication and mitosis [115].
Lu et al. [1] revealed by recombinant ELISA the presence
of AAbs to TOPO2α protein in the sera of 8/115 (7%)
breast carcinoma patients compared to 4/200 (2%) healthy
controls. It seems that serum AAbs to TOPO2α have no
diagnostic potential in breast carcinoma when examined
alone; however, they may possibly have diagnostic potential
when incorporated in autoantibody assays against a panel of
TAAs.
16. Autoantibodiesto CathepsinDProtein
Primarybiologicalfunctionofenzymaticallyactivecathepsin
D is protein degradation in an acidic milieu of lysosomes
[116]. Failure of this function resulted in accumulation
of lipofuscin in variety of cell types, neurodegeneration,
developmental regression, and visual loss. Procathepsin D,
secreted from cancer cells, acts as a mitogen on both
cancer and stromal cells and stimulates their proinvasive and
prometastatic properties. Procathepsin D/cathepsin D levels
represent an independent prognostic factor in a variety of
cancers [116].
Using recombinant ELISA, Lu et al. [1]d e t e c t e dA A b s
to cathepsin D protein in the sera of 5/100 (5%) breast10 Journal of Oncology
carcinoma patients compared to 3/100 (3%) healthy con-
trols. It seems that serum AAbs to cathepstin D have no
diagnostic potential in breast carcinoma when examined
alone; however, they may possibly have diagnostic potential
when incorporated in autoantibody assays against a panel of
TAAs.
17. Conclusions andPersonalViewpoints
Breast carcinoma is the most common malignancy and
the most frequent cause of death from cancer in women.
Traditionaldiagnostictoolsforearlydetection,namely,man-
ual breast examination, imaging studies (mammography,
ultrasound, and MRI), and measurement of serum CA-15-3
are crippled with insuﬃcient sensitivity and speciﬁcity. The
mean sensitivity of mammography has been estimated to be
77%(range:29%–97%)[117–119].Therateoffalse-negative
mammography has been reported to be 4%–34% [120, 121].
SerumAAbstospeciﬁcTAAsaredetectableincancerpatients
even when the tumor is obscured clinically. Evidently, the
human immune system recognizes the autologous TAAs as
“nonself” and makes a humoral immune response very early
inthediseaseprocess.Thus,theidentiﬁcationofserumAAbs
to TAAs could potentially be used as a novel tool for screen-
ing and early diagnosis of breast carcinoma. Nevertheless, it
has been shown that measurement of AAbs against a single
TAA is of little value and only assessment of AAbs to a
tailor-made panel of TAAs may have promising diagnostic
potential. The implications of this would be that AAbs to
TAAs would provide a simple blood test for screening and
early diagnosis of breast carcinoma. Nevertheless, it must
be remembered that measurement of serum AAbs to TAAs
for screening and early diagnosis of breast carcinoma is
still investigational and should be carried out along with
traditional screening and diagnostic studies. Our personal
viewpoints regarding the management of women having a
blood test for serum AAbs to breast carcinoma TAAs are as
follows.
(1) Women with mammography ﬁndings that are highly
suggestive of breast carcinoma (BI-RADS category
5) or suspicious for breast carcinoma (BI-RADS
category 4) [122] would require an immediate breast
biopsy to obtain tissue for histological diagnosis
irrespective of the status of serum AAbs to breast
carcinoma TAAs.
(2) In women with probably benign ﬁndings on mam-
mography (BI-RADS category 3) [122], presence
of serum AAbs to breast carcinoma TAAs would
strengthen the decision to perform an immediate
breast biopsy to obtain tissue for histological diag-
nosis rather than to wait six months for the next
mammography. On the other hand, in women with
probably benign ﬁndings on mammography (BI-
RADS category 3), absence of serum AAbs to breast
carcinoma TAAs would support the decision to wait
six months for the next mammography.
(3) In women with negative ﬁndings on mammography
(BI-RADS category 1) and in women with benign
ﬁnding(s) on mammography (BI-RADS category 2)
[122], presence of serum AAbs to breast carcinoma
TAAs might lead to a decision to perform immediate
additional imaging studies (ultrasound and/or MRI)
or, in women with BI-RADS category 2, even an
immediate breast biopsy to obtain tissue for histo-
logical diagnosis rather than to wait one year for
the next routine annual screening mammography.
On the other hand, in women with negative ﬁndings
on mammography (BI-RADS category 1) and in
women with benign ﬁnding(s) on mammography
(BI-RADS category 2) [122], absence of serum AAbs
tobreastcarcinomaTAAswouldsupportthedecision
to wait one year for the next routine annual screening
mammography.
(4) Women with an incomplete mammography assess-
ment (BI-RADS category 0) [122] would need
immediate additional imaging evaluation (ultra-
sound and/or MRI) and/or prior mammograms
for comparison irrespective of the status of serum
AAbs to breast carcinoma TAAs. Nevertheless, the
p r e s e n c eo fs e r u mA A b st ob r e a s tc a r c i n o m aT A A s
in such women would hasten the assessment by
additional imaging studies and might even bring to
the performance of an immediate breast biopsy to
obtain tissue for histological diagnosis.
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